CHA Vaccine Research Institute (KOSDAQ:261780)
South Korea · Delayed Price · Currency is KRW 2,635.00
0.00 (0.00%)
At close: Feb 19, 2026
KOSDAQ:261780 Revenue
CHA Vaccine Research Institute had revenue of 158.62M KRW in the twelve months ending September 30, 2025, down -57.21% year-over-year. In the year 2024, CHA Vaccine Research Institute had annual revenue of 370.66M with 26.02% growth.
Revenue (ttm)
158.62M
Revenue Growth
-57.21%
P/S Ratio
444.60
Revenue / Employee
n/a
Employees
n/a
Market Cap
70.52B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 370.66M | 76.53M | 26.02% |
| Dec 31, 2023 | 294.12M | 114.64M | 63.87% |
| Dec 31, 2022 | 179.48M | -320.52M | -64.10% |
| Dec 31, 2021 | 500.00M | 422.20M | 542.70% |
| Dec 31, 2020 | 77.80M | -48.32M | -38.31% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cell Biotech | 50.65B |
| Choong Ang Vaccine Laboratory | 39.19B |
| Ark Solutions | 21.50B |
| PanGen Biotech | 15.27B |
| NGeneBio | 9.98B |
| HLB Pep | 4.89B |
| EyeGene | 4.10B |
| SunBio,Inc. | 2.17B |